ClinicalTrials.gg
CompletedNCT06643156Updated Mar 18, 2025

Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension

A Phase 1 interventional study of GP681 10mg/20mg/40mg in Influenza, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Completed at 1 site in China. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Enrollment
145th of 157
44 · median 360
Started
2024
with 16 others
Phase 1
25 of 173
2 open now
Registered
136th of 173
by date
Lead sponsor
7 of 173
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Among the 173 studies in Influenza, Human with a site in China, this one is the 145th largest by enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2024, is one of 25 in phase 1, and was the 136th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the tolerability, safety, pharmacokinetic characteristics and efficacy of a single oral dose of GP681 powder for oral suspension in pediatric and adolescent patients with uncomplicated influenza. The study will also explore the optimal dose for a confirmatory clinical trial. Eligible patients who have been confirmed influenza virus infection and have experienced influenza symptoms within 48 hours prior to enrollment, will receive single dose of GP681 powder for oral suspension. The primary outcome measures included the observation of adverse events during the study, the pharmacokinetic parameters, as well as the efficacy endpoints including time to alleviation of influenza symptoms, viral clearance rate, changes in viral load, etc.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 2 to 18 years (≥2 years and \<18 years).
  2. For participants aged 5 to 18 years (excluding 18 years): body weight ≥20 kg; for participants aged 2 to 5 years (excluding 5 years): 10 kg≤body weight \<20 kg.
  3. Diagnosed with influenza virus infection based on the following criteria: • Positive rapid antigen test (RAT) result from a throat or nasal swab for influenza virus (rapid nucleic acid tests or other rapid molecular diagnostic tests are also acceptable); and

    • Fever at screening (axillary temperature ≥37.5°C). If antipyretics have been administered, axillary temperature should be ≥37.5°C at least 1 hour after administration, or fever (axillary temperature \<37.5°C) that returns to ≥37.5°C more than 4 hours after antipyretic use; and
    • At least one moderate or severe respiratory symptom at screening, including cough and/or nasal congestion or runny nose.
  4. Time interval between the onset of illness symptoms and enrollment is ≤48 hours.

    Onset of illness: defined as the time of the first temperature increase (axillary temperature ≥37.5°C) or the time when at least one respiratory symptom related to influenza virus infection is first noticed by caregiver.

  5. The participant's legal guardian agrees to the child's participation in the clinical study and signs the form (ICF). Participants aged ≥8 years must also voluntarily sign the ICF.
  6. The investigator assesses that the participant and/or the caregiver can comply with the protocol requirements, follow-up visits, and complete all study procedures and evaluations, including diary card entries.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the active ingredients or of the drug GP681.
  2. Patients diagnosed with severe or critical influenza at screening: (1) Severe influenza cases were defined by the presence of one or more of the following conditions: a. Breathing difficulty and/or increased respiratory rate: >30 breaths/min for children >5 years old, >40 breaths/min for children aged 2-5 years; b. Consciousness alteration: slow response, somnolence, agitation, seizures, etc; c. Severe vomiting or diarrhea with moderate or severe dehydration; d. Pneumonia; e. Significant exacerbation of underlying diseases. (2) Critical influenza cases were defined by the presence of one or more of the following conditions: a. Respiratory failure; b. Acute necrotizing encephalopathy; c. Septic shock; d. Multiple organ dysfunction; e. Other severe clinical conditions requiring intensive care treatment.

    Note: Refer to the "Expert Consensus on Diagnosis and Treatment of Influenza in Children (2020 Edition)" for the criteria of severe/critical influenza.

  3. History of any gastrointestinal disease known to affect drug absorption (including but not limited to gastroesophageal reflux disease, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, or post-gastrectomy conditions).
  4. Suspected or confirmed bronchitis, pleural effusion, or interstitial pneumonia via clinical or radiological examination at screening.
  5. Use of anti-influenza antiviral drugs within two weeks before screening (including neuraminidase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers such as oseltamivir phosphate, zanamivir, peramivir, favipiravir, arbidol, baloxavir, amantadine, or rimantadine, or other anti-influenza antiviral drugs approved by the NMPA).
  6. abnormal results in physical examination, 12-lead , vital signs, hematology, clinical biochemistry, or urinalysis at screening, which in the investigator's judgment may pose a risk to the participant's safety, affect the study results, or impact the participant's ability to complete the study.
  7. Acute respiratory tract infection, otitis media, or sinusitis within two weeks before screening.
  8. Co-infection requiring systemic antibiotics or other systemic therapy at screening.
  9. Known or suspected active primary or secondary immunodeficiency, including a history of infection or other severe immunodeficiencies.
  10. Known or suspected congenital abnormalities of the heart or lungs, or severe primary diseases affecting the cardiovascular, hepatic, renal, or hematopoietic systems, or evidence of active liver disease, including but not limited to jaundice or /ALT levels exceeding two times the (ULN) at screening.
  11. Positive serology for surface antigen or a history of hepatitis B infection at screening.

    Note: Children and adolescents with a history of hepatitis B vaccination without a history of hepatitis B infection do not need to be screened for this criterion (assessed via medical history).

  12. Obesity as determined by the investigator: For participants \<6 years old: >97th percentile for the corresponding age and gender group; For participants ≥6 years old: BMI ≥obesity threshold for the corresponding age and gender group.

    Note: Refer to "WS/T 423-2022: Growth Standards for Children Under 7" or "WS/T586-2018: Screening for Overweight and Obesity in School-Aged Children and Adolescents."

  13. History of mental illness, intellectual disability, substance abuse, or other adverse conditions (e.g., inability to read, understand, or write) that, in the investigator's judgment, may limit participation in the study.
  14. Vaccination with an influenza vaccine within six months before screening or during the study period.

    Note: Participants' influenza vaccination history should be carefully reviewed before study enrollment (assessed via medical history).

  15. Participation in a clinical trial of any investigational drug or device for any indication within 30 days prior to screening.
  16. Intolerance to skin puncture, fainting at the sight of blood or needles, or poor venous access for blood collection at screening.
  17. Other conditions judged by the investigator to be unsuitable for participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    GP681 powder for oral suspension 10mg/20mg/40mg

    All patients will receive a single oral dose of GP681 dry suspension dissolved in approximately 10 mL of warm water. The mixture will be stirred thoroughly before administration, and then the cup will be rinsed twice with an additional 10-20 mL of warm water (about 40°C) to ensure the full dose is taken. The dosage of GP681 in patients 2-18 years of age is a single weight-based dose displayed in the following table. Dosage Patients 40mg Aged 5-18years(exclusive),weight≥40kg 20mg Aged 5-18years(exclusive),20kg≤weight\<40kg 40mg Aged 5-18years(exclusive),20kg≤weight\<40kg 10mg Aged 2-5years(exclusive),10kg≤weight\<20kg 20mg Aged 2-5years(exclusive),10kg≤weight\<20kg

    Drug: GP681 10mg/20mg/40mg

Interventions

  • DrugGP681 10mg/20mg/40mg

    0.5/1/2×20mg power for oral suspension taken orally

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: up to Day 15

Secondary outcomes

  1. Time to Alleviation of Symptoms (TTAS)

    Defined as the time from the treatment start to meeting both the following criteria (a and b), with all criteria maintained for at least 21.5 hours: a. Time from treatment initiation to the normalization of body temperature (axillary temperature ≤37.4°C).

    Time frame: up to Day 15

  2. Viral clearance rate on Day 2 and Day 5 (if applicable)

    Defined as the proportion of patients with viral titers below the quantifiable detection limit from the treatment start to Day 2 and Day 5 (if applicable)

    Time frame: Days 2, 5

  3. Proportion of patients with influenza viral RNA positivity (by Q-PCR) and measurable viral titers at each time point (Day 2 and Day 5, if applicable)

    The percentage of patients positive for virus RNA by RT-PCR.Virus titer was quantified from nasopharyngeal swabs by tissue culture methods.

    Time frame: Days 2, 5

  4. Area Under the Concentration (AUC) of virus RNA by RT-PCR and AUC of virus titer

    AUC of the viral load by RT-PCR and AUC of viral titer measured from baseline to Day 5

    Time frame: Up to Day 5

  5. Change From Baseline in Virus RNA (RT-PCR) at Each Time Point

    Nasopharyngeal swabs were obtained for viral quantitation.

    Time frame: Days 2, 5

  6. Time to Resolution of Fever

    Defined as the time to a score of 0 (none) or 1 (mild) for individual symptoms from the 16 items on the CARIFS scale, sustained for at least 21.5 hours.

    Time frame: Up to Day15

  7. Time to return to normal activities of daily life

    Defined as the time between the initiation of the study treatment and the return to normal activities of daily life.

    Time frame: Up to Day15

  8. Incidence of influenza-related complications

    Defined as the percentage of subjects in the analysis population who experience each influenza-related complication (hospitalization, death, sinusitis, bronchitis, otitis media, and pneumonia) as an adverse event after the initiation of the study treatment.

    Time frame: Up to Day15

07

Study locations

1 site
  • Ningbo Women and Children's hospital
    Ningbo, Zhejiang 315042, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2025, 3 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 16, 2024
StartActual
Sep 27, 2024
Primary completionActual
Jan 18, 2025
CompletionActual
Jan 18, 2025
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06643156
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Sep 27, 2024
Primary completion
Jan 18, 2025
Completion
Jan 18, 2025
Last update
Mar 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion